Annotation Detail

Information
Associated Genes
NTRK3
Associated Variants
NTRK3 NTRK3 FUSIONS NTRK3 NTRK3 FUSIONS
Associated Disease
cancer
Source Database
CIViC Evidence
Description
in two phase I studies in patients with advanced or metastatic solid tumors, including patients with active central nervous system (CNS) disease. Here, we summarize the overall safety and report the antitumor activity of entrectinib in a cohort of patients with tumors harboring NTRK1/2/3, ROS1, or ALK gene fusions Responses were observed in non-small cell lung cancer, colorectal cancer, mammary analogue secretory carcinoma, melanoma, and renal cell carcinoma, as early as 4 weeks after starting treatment and lasting as long as >2 years. Notably, a complete CNS response was achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/2949
Gene URL
https://civic.genome.wustl.edu/links/genes/3985
Variant URL
https://civic.genome.wustl.edu/links/variants/1277
Rating
3
Evidence Type
Predictive
Disease
Cancer
Evidence Direction
Supports
Drug
Entrectinib
Evidence Level
B
Clinical Significance
Sensitivity/Response
Pubmed
28183697
Drugs
Drug NameSensitivitySupported
EntrectinibSensitivitytrue